Zobrazeno 1 - 10
of 270
pro vyhledávání: '"David, Fitchett"'
Autor:
David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren S. Lund
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-7 (2024)
Abstract Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME
Externí odkaz:
https://doaj.org/article/e033bb1ddc7949bca3ef1b0df0c3d965
Autor:
Ayodele Odutayo, MD, DPhil, Bernard Zinman, MD, Christoph Wanner, MD, Isabella Zwiener, PhD, Søren S. Lund, MD, Stefan Hantel, PhD, David Fitchett, MD, Jacob A. Udell, MD
Publikováno v:
CJC Open, Vol 6, Iss 7, Pp 868-875 (2024)
Background: In patients with type 2 diabetes mellitus (T2DM), a history of an ischemic event is associated with increased risk for cardiovascular (CV) disease. Whether patients with T2DM and a recent atherothrombotic diagnosis benefit from early inte
Externí odkaz:
https://doaj.org/article/12704b8390a44fb594728043a80151c6
Autor:
Abhinav Sharma, Silvio E. Inzucchi, Jeffrey M. Testani, Anne Pernille Ofstad, David Fitchett, Michaela Mattheus, Subodh Verma, Faiez Zannad, Christoph Wanner, Bettina J. Kraus
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 737-747 (2024)
Abstract Aims This study aimed to evaluate the bidirectional relationship between kidney and cardiovascular (CV) events in trial participants with type 2 diabetes and CV disease. Methods and results Post hoc analyses of EMPA‐REG OUTCOME using Cox r
Externí odkaz:
https://doaj.org/article/d6eba344c35f43a9afd5fa5b83bba977
Autor:
Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, David Fitchett, Anne Pernille Ofstad, Christoph Wanner, Michaela Mattheus, Bernard Zinman, Patrick R. Lawler, Lawrence A. Leiter
Publikováno v:
American Journal of Preventive Cardiology, Vol 15, Iss , Pp 100510- (2023)
Objectives: REDUCE-IT showed that icosapent ethyl (IPE) improved cardiovascular (CV) outcomes in participants with established CV disease (CVD) or type 2 diabetes (T2D) and at least one additional risk factor plus mild-moderate hypertriglyceridemia a
Externí odkaz:
https://doaj.org/article/d083c1a8463845e48238f05fb086aa8d
Autor:
David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, Faiez Zannad
Publikováno v:
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
Abstract Aims In the EMPA‐REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV)
Externí odkaz:
https://doaj.org/article/6f3f85051982443390d12385e07f958a
Autor:
Subodh Verma, Lawrence A. Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis George, Anne Pernille Ofstad, Mikhail N. Kosiborod, Christoph Wanner, Silvio E. Inzucchi
Publikováno v:
ESC Heart Failure, Vol 8, Iss 4, Pp 2603-2607 (2021)
Abstract Aims In the EMPA‐REG OUTCOME trial, in patients with type 2 diabetes and established atherosclerotic cardiovascular (CV) disease, empagliflozin vs. placebo reduced the risk of hospitalization for heart failure (HHF) by 35%, CV death/HHF by
Externí odkaz:
https://doaj.org/article/35bbcdb9f370489588adedc3953e2157
Autor:
Pierpaolo Pellicori, Anne Pernille Ofstad, David Fitchett, Cordula Zeller, Christoph Wanner, Jyothis George, Bernard Zinman, Martina Brueckmann, JoAnn Lindenfeld
Publikováno v:
ESC Heart Failure, Vol 7, Iss 6, Pp 3401-3407 (2020)
Abstract Aims The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV d
Externí odkaz:
https://doaj.org/article/b6fd846244c241c3a346f6cbbd89db9f
Autor:
João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman, Silvio E. Inzucchi
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-9 (2020)
Abstract Background Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and the effect
Externí odkaz:
https://doaj.org/article/23da6e38cf0e451d8d683f1bd8ab82d5
Autor:
Anne Pernille Ofstad, Afshin Salsali, Erich Bluhmki, Martin Schumacher, Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, Stefan Hantel, Kristin Ohneberg, Jyothis T. George, Claudia Schmoor, David Fitchett, Faiez Zannad, Bernard Zinman
Publikováno v:
ESC Heart Failure
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
International audience; Aims: In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c9cd3965f69a6842aa5748f13ebd7d
https://doi.org/10.1002/ehf2.13615
https://doi.org/10.1002/ehf2.13615
Autor:
Christoph Wanner, Isabella Zwiener, Robert J. Mentz, Jyothis T. George, Abhinav Sharma, David Fitchett, Nihar R. Desai, Bernard Zinman, Anne Pernille Ofstad, Stefan Hantel, Tariq Ahmad
Publikováno v:
JACC: Heart Failure. 9:568-577
Objectives Using latent class analysis (LCA) of EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), this study identified d...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8309ebe470180d8fe8154900de90b795
https://doi.org/10.1016/j.jchf.2021.03.003
https://doi.org/10.1016/j.jchf.2021.03.003